Hepion Pharmaceuticals (HEPA) Announces Receipt of Delisting Notification from Nasdaq May 12, 2025 04:30PM
Hepion Pharmaceuticals (HEPA) Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC May 7, 2025 08:31AM
Hepion Pharmaceuticals (HEPA) Announces 1-for-50 Reverse Stock Split Mar 14, 2025 08:30AM
Hepion Pharmaceuticals (HEPA) Prices $9M Offering Jan 22, 2025 08:00AM
Hepion Pharmaceuticals (HEPA) Terminates Merger Agreement with Pharma Two B Ltd. Dec 11, 2024 08:01AM


Dec 2, 2024 08:01AM Hepion Pharmaceuticals (HEPA) Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Nov 11, 2024 08:03AM Pharma Two B and Hepion Pharmaceuticals (HEPA) Announce Effectiveness of Registration Statement Related to Proposed Merger
Sep 4, 2024 09:26AM Hepion Pharmaceuticals (HEPA) and Pharma Two B File Registration Statement on Form F-4 Related to Proposed Merger
Jul 22, 2024 08:03AM Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals (HEPA) and Concurrent $11.5 Million Private Placement